30th week of 2020 patent applcation highlights part 23 |
Patent application number | Title | Published |
20200231549 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 - The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer. | 2020-07-23 |
20200231550 | COMPOUNDS FOR TREATING TUBERCULOSIS - The present invention relates to pyrimidine compounds and compositions for treating tuberculosis. These compounds may be used to target the F | 2020-07-23 |
20200231551 | COMPOSITIONS AND USES THEREOF - The disclosure is directed to compounds of the formula (IA), (I)-(V) and others disclosed herein and uses of such compounds. | 2020-07-23 |
20200231552 | NOVEL POLYMORPS OF CARIPRAZINE HYDROCHLORIDE AND PREPARATION METHOD THEREOF AND USE OF SAME - The present disclosure discloses crystal forms A, B, and C of trans-N-{4-[2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl]-cyclohexyl}-N′,N′-dimethylurea hydrochloride, a preparation method, and a medicinal use thereof. Compared to the existing crystalline forms, the new crystalline forms have clear advantages with respect to solubility, stability, and the preparation process. | 2020-07-23 |
20200231553 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE - The disclosed subject matter provides methods using and kits comprising a compound of formula (I) | 2020-07-23 |
20200231554 | LIPOPHILIC MACROCYCLIC LIGANDS, COMPLEXES THEREOF, AND USES OF SAME - The present invention relates to novel lipophilic macrocyclic ligands, the complexes thereof, in particular radioactive complexes, and the uses of same in medical imaging and/or in therapy, in particular in interventional radiology. | 2020-07-23 |
20200231555 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS - The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by | 2020-07-23 |
20200231556 | PREPARATION OF SUBSTITUTED 3-ARYL-5-TRIFLUOROMETHYL-1,2,4-OXADIAZOLES - The present invention relates to a process for the preparation of 3-aryl-5-trifluoromethyl-1,2,4-oxadiazoles, which are useful as fungicidal compounds or as intermediates for the synthesis of fungicidal oxaciazole compounds, using trifluoroacetyl halides. | 2020-07-23 |
20200231557 | PROCESSES FOR PREPARING 2,5-FURANDICARBOXYLIC ACID AND ESTERS THEREOF - A process for producing furan dicarboxylic acid or an ester thereof from a feedstock comprising hydroxymethyl furfural (HMF) and humins is disclosed. Humins are a byproduct from reactions forming HMF from sugars and are typically removed from the HMF prior to any further processing. A humins-containing HMF feedstock is utilized to produce furan dicarboxylic acids and ester substantially free from humins. | 2020-07-23 |
20200231558 | PROCESSES FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND INTERMEDIATES AND DERIVATIVES THEREOF - The present disclosure provides processes for the production of 2-5-furandicarboxylic acid (FDCA) and intermediates thereof by the chemocatalytic conversion of a furanic oxidation substrate. The present disclosure further provides processes for preparing derivatives of FDCA and FDCA-based polymers. In addition, the present disclosure provides crystalline preparations of FDCA, as well as processes for making the same. | 2020-07-23 |
20200231559 | HYDROPHILIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES - The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic devices comprising such compounds. | 2020-07-23 |
20200231560 | POLYPHENOL PRODUCTION METHOD - [PROBLEM] To provide a novel method for synthesising a polyphenol. | 2020-07-23 |
20200231561 | PLANT EXTRACTS ENRICHED WITH IPOLAMIIDE DERIVATIVES AS IMMUNOSUPPRESSANTS FOR TREATING IMMUNOLOGICAL DISORDERS - The invention describes extracts from plants of the genus | 2020-07-23 |
20200231562 | NOVEL MACROLIDE ANTIBIOTICS - The present invention relates to a compound according to general formula (I), which exhibits bioactivity; methods for the production of the compound; to pharmaceutical compositions comprising one or more of the compound(s); and to the use of the compound(s) as a medicament. | 2020-07-23 |
20200231563 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 - The present invention relates to novel heterocyclic compounds. The invention is also directed to compounds which are modulators of the metabotropic glutamate receptors (m Glu R), preferably of the metabotropic glutamate receptor subtype 7 (“m Glu R7”). The present invention also relates to pharmaceutical composition comprising such compounds and their use for the treatment or prevention of disorders associated with glutamate dysfunction or in which metabotropic glutamate receptor, preferably m Glu R7 subtype of metabotropic glutamate receptors, is involved. | 2020-07-23 |
20200231565 | PYRIDINIUM COMPOUNDS, A SYNTHESIS METHOD THEREFOR, METAL OR METAL ALLOY PLATING BATHS CONTAINING SAID PYRIDINIUM COMPOUNDS AND A METHOD FOR USE OF SAID METAL OR METAL ALLOY PLATING BATHS - The present invention concerns pyridinium compounds, a synthesis method for their preparation, metal or metal alloy plating baths containing said pyridinium compounds and a method for use of said metal or metal alloy plating baths. | 2020-07-23 |
20200231566 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 2020-07-23 |
20200231567 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME - Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed. | 2020-07-23 |
20200231568 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS - The present invention provides a compound of formula (I) or a pharmaceutical salt thereof, use, methods for its preparation are described. | 2020-07-23 |
20200231569 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF - The present disclosure provides a compound of Formula (I′): | 2020-07-23 |
20200231570 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS - Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology. | 2020-07-23 |
20200231571 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV - Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions. | 2020-07-23 |
20200231572 | NOVEL BIS-CYCLIC GUANIDINES AS ANTIBACTERIAL AGENTS - Provided are novel bis-cyclic guanidine compounds, and the use thereof for treating bacterial infection. | 2020-07-23 |
20200231573 | Fluorene Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Therefor, and Pharmaceutical Composition Comprising Same as Effective Ingredient for Preventing or Treating HCV-Related Disease - The present invention relates to a fluorene derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition comprising the same as an effective ingredient for preventing or treating HCV-related disease. A fluorene derivative according to the present invention is identified to exhibit an antiviral performance against not only HCV, but also highly against HCV mutants, particularly double mutants and thus can be used in a pharmaceutical composition for prevention or treatment of HCV-caused liver disease, such as acute hepatitis C, chronic hepatitis C, liver cirrhosis, hepatocellular cancer, etc., particularly, liver disease caused by mutants of HCV. The derivative can be useful in a pharmaceutical composition for prevention or treatment of HCV-related liver disease by which the problem of resistant mutation against conventional therapeutic agents is solved. | 2020-07-23 |
20200231574 | HALOGEN COMPLEXES OF COMPOUNDS COMPRISING AT LEAST ONE ETHER, THIOETHER, AND/OR IMINE MOIETY AND AT LEAST TWO LACTAM MOIETIES - The disclosed and/or claimed inventive concept(s) provides a complex of at least one halogen and a compound comprising at least one ether, thioether, and/or imine moiety and at least two lactam moieties. The disclosed and/or claimed inventive concept(s) further provides compositions comprising the complexes and applications thereof in various industrial areas including personal care, home care, pharmaceuticals, antimicrobials, disinfectants, biocides, germicides, and coatings. | 2020-07-23 |
20200231575 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-,N-[PYRIDYLAMINO)PROPANYL]- AND N-[(PYRAZINYLAMINOL)PROPANYL]ARYLCARBOXAMIDES - The present invention relates to novel N-[(Pyrimidinylamino)propanyl]-, N-[(Pyridylamino)propanyl]- and N-[(Pyrazinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor. | 2020-07-23 |
20200231576 | VINYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS - The present invention provides compounds having formula (I): and pharmaceutically acceptable salts thereof, wherein Cy1, Cy2, Cy3, R, R | 2020-07-23 |
20200231577 | ARYL SUBSTITUTED PYRIMIDINES FOR USE INFLUENZA VIRUS INFECTION - The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections. | 2020-07-23 |
20200231578 | COMPOSITION FOR ORGANIC ELECTRONIC DEVICES - The present invention relates to a composition which comprises an electron-transporting host and a hole-transporting host, to the use thereof in electronic devices and to electronic devices containing this composition. The electron-transporting host is particularly preferably selected from the class of the triazine-dibenzofuran-carbazole systems or the class of the triazine-dibenzothiophene-carbazole systems. The hole-transporting host is preferably selected from the class of the biscarbazoles. | 2020-07-23 |
20200231579 | HETEROCYCLIC COMPOUND - Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): | 2020-07-23 |
20200231580 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT INCLUDING SAME - The present invention relate to a novel organic compound and an organic electroluminescent device including the same, and in particular, to a novel dibenzofuran-based compound having excellent thermal stability, carrier transport ability, light emitting ability and the like, and an organic electroluminescent device having low driving voltage, and enhanced luminous efficiency, lifetime properties and the like by including the novel dibenzofuran-based compound as a material of one or more organic material layers. | 2020-07-23 |
20200231581 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF - The present invention provides the compound represented by Formula 1, an organic electric element comprising a first electrode, a second electrode, and an organic material layer formed between the first electrode and the second electrode, and electronic device thereof, and by comprising the compound represented by Formula 1 in the organic material layer, the driving voltage of the organic electronic device can be lowered, and the luminous efficiency and life time of the organic electronic device can be improved. | 2020-07-23 |
20200231582 | ETHER COMPOUNDS AND USES THEREOF - The present invention provides compounds that modulate protein function, to restore protein homeostasis and/or cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions of these compounds are also provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions are also provided. | 2020-07-23 |
20200231583 | Prostaglandin E Synthase Inhibitors and Methods for Utilizing the Same - Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or symptoms thereof. Pharmaceutical compositions comprising the compound are also provided. Furthermore, methods are provided for reducing inflammation and/or inhibiting mPGES-1. The methods can comprise administering an effective amount of the composition to a subject. | 2020-07-23 |
20200231584 | PCSK9 Inhibitors and Methods of Use Thereof - The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein. | 2020-07-23 |
20200231585 | CYCLOPROPYL FUSED THIAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE - The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I) wherein variables A, R | 2020-07-23 |
20200231586 | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS - A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of one or more CDK enzyme and/or by one or more aberrant CDK activity, including certain cancers of lung, breast, brain, ovary, prostate, colorectal cancer and leukaemias. The inhibitors have the general structure (I). | 2020-07-23 |
20200231587 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD CONTROLLING AGENT CONTAINING SAME - A composition containing a compound having excellent controlling effects against a harmful arthropod is represented by formula (I). In formula (I), Q represents a group represented by formula Q1; a group represented by formula Q2 or a group represented by formula Q3; a combination of A | 2020-07-23 |
20200231588 | Bicyclic Heteroaryl Compounds - This invention relates to compounds of the general formula: | 2020-07-23 |
20200231589 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF - 1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology. | 2020-07-23 |
20200231590 | IMIDAZOLE AND TRIAZOLE CONTAINING BICYCLIC COMPOUNDS AS JAK INHIBITORS - The invention provides compounds of formula (I): | 2020-07-23 |
20200231591 | FUSED RING HETEROARYL COMPOUNDS AS ALK4/5 INHIBITORS - The invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of ALK5 and/or ALK4 and are useful in the treatment of pulmonary fibrosis, NASH, obesity, diabetes, cancers and other inflammation. | 2020-07-23 |
20200231592 | SUBSTITUTED 2-(4-HETEROCYCLYLBENZYL)ISOINDOLIN-1-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 - In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M | 2020-07-23 |
20200231593 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT - Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 2020-07-23 |
20200231594 | TYK2 INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders. | 2020-07-23 |
20200231595 | CRYSTALLINE FORMS OF A BRUTONS TYROSINE KINASE INHIBITOR - Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2020-07-23 |
20200231596 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE - Described herein, are the chemical synthesis, matter of compositions, formulation, function, methods and uses of the FL118 platform Positions 7 and/or 9-derived analogues for treating cancer or other human diseases. Compounds derived from chemical modifications of the FL118 platform are employed alone or in combination with other anti-cancer agents to preclude, eliminate or reverse cancer phenotypes. This invention intends to realize unique personalized cancer treatment (personalized precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogues, which target multiple cellular human disease-relevant proteins and their signaling pathways. | 2020-07-23 |
20200231597 | BICYLIC COMPOUND ACTING AS AN INHIBITOR - A bicyclic compound acting as a RORγ inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good RORγ inhibitory activities, being expected to be used for treating diseases mediated by RORγ receptors in a mammal. | 2020-07-23 |
20200231598 | PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS - The invention relates to compounds of the formula: | 2020-07-23 |
20200231599 | 2-OXO-1,3-OXAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES - The present invention relates to 2-oxo-1,3-oxazolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2020-07-23 |
20200231600 | SUBSTITUTED AMINOTHIAZOLOPYRIMIDINEDIONES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION - The present invention relates to compounds of formula (I), | 2020-07-23 |
20200231601 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE - The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, X, R | 2020-07-23 |
20200231602 | ORGANIC COMPOUND AND ELECTROLUMINESCENT DEVICE CONTAINING THE SAME - An organic compound having the structure of Formula (I), shown below, is disclosed. When used in a hole injection layer or a hole transporting layer, it can greatly improve the balance of electron holes and electron transporting of a device, thereby bringing excellent device effects, for example, improving the efficiency and lifetime of a device. At the same time, it also achieves a good effect when the organic compound having the structure of Formula (I) is used as a P-type conductive doping material in a charge generation layer of a multi-layer OLED device. | 2020-07-23 |
20200231603 | METHOD OF SYNTHEZING METAL-ASCORBIC ACID CRYSTALS - The invention provides metal-ascorbic acid crystals and a method for synthesizing the metal-ascorbic acid crystals. The metal in the metal-ascorbic acid crystals is one of copper (Cu), gold (Au) and silver (Ag). The method for synthesizing the metal-ascorbic acid crystals includes sonicating a solution of ascorbic acid and a solvent in dark to obtain a clear solution, wherein the solvent is one of dimethylformamide (DMF) and dimethyl sulfoxide (DMSO). A metal salt is added to the clear solution, wherein the metal salt is one of copper (II) sulfate pentahydrate (CuSO | 2020-07-23 |
20200231604 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES - An organic molecule is disclosed having a structure of Formula I: | 2020-07-23 |
20200231605 | NOVEL COMPOUNDS, FUNCTIONALISED DIOXABOROLANE OR DIOXABORINANE DERIVATIVES, METHOD FOR PREPARING SAME AND USES THEREOF - The invention relates to functionalised dioxaborolane or dioxaborinane derivatives of formula (I), wherein R | 2020-07-23 |
20200231606 | NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS - Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. | 2020-07-23 |
20200231607 | TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES - The present disclosure relates to fungicidal active compounds, more specifically to trisubstitutedsilylphenoxyheterocycles and analogues thereof, processes and, intermediates for their preparation as well as use thereof as fungicidal active compound, particularly in the form of fungicide compositions. The present disclosure also relates to methods for the control of phytopathogenic fungi of plants using these compounds or compositions comprising thereof. | 2020-07-23 |
20200231608 | SILOXANE COMPOUND AND A METHOD FOR PREPARING THE SAME - An object of the present invention is to provide a monomer having a polysiloxane structure and capable of providing a polymer having sufficient compatibility and hydrolysis resistance while having high oxygen permeability useful for an ophthalmic device, and a method for producing the monomer. | 2020-07-23 |
20200231609 | ALKOXYSILANE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, AND HAIR COMPOSITION CONTAINING SAME - The present invention relates to an alkoxysilane salt compound having a novel structure, a preparation method therefor, and a hair composition containing the same. The alkoxysilane salt compound increases the storage stability and the dispersion stability of a hair composition in accordance with the formation of a self-assembly in the aqueous phase and can provide a continuous conditioning effect for hair. | 2020-07-23 |
20200231610 | TIN COMPOUND, TIN PRECURSOR COMPOUND FOR FORMING A TIN-CONTAINING LAYER, AND METHODS OF FORMING A THIN LAYER USING THE SAME - A tin compound, a tin precursor compound for forming a tin-containing layer, and a method of forming a thin layer, the tin compound being represented by Formula 1: | 2020-07-23 |
20200231611 | Method to Synthesize Metal Halide Perovskite Particles with High Luminescence and Stability - The invention provides a convenient solution-based synthesis for metal halide perovskite particles. This method requires only mild conditions and can be easily scaled up. A ligand of a proper molecule size and an optimized precursor ratio are important to obtain pure phase particles. As an example, lead bromide perovskite particles exhibited a narrow monochromatic band gap, which can be tuned by partial halide substitution, and PLQY up to 75% making this material an excellent candidate for light emission and display applications. | 2020-07-23 |
20200231612 | Method for Producing Herbicide Intermediate - A method for producing methyldichlorophosphane, the method including: allowing methane and phosphorus trichloride to react in the presence of an additive using a metal compound, or a metal compound carried on a carrier, or both thereof. | 2020-07-23 |
20200231613 | PHOSPHINE OXIDES REDUCTION - Provided is a process for the conversion of a tertiary phosphine oxide to the corresponding tertiary phosphine, comprising at least reacting said tertiary phosphine oxide with a phosphite compound, in the presence of at least a catalyst. Furthermore, provided is a composition comprising at least a tertiary phosphine oxide and a phosphite compound, and optionally a catalyst. | 2020-07-23 |
20200231614 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY - PPSMA binding scaffolds with radioiodinated, radiobrominated and radioastatinated labeled prosthetic groups are disclosed. Pharmaceutical compositions and methods of treating PSMA expressing cells or tumors also are disclosed. | 2020-07-23 |
20200231615 | Metal Tricarbonyl Complexes Comprising Substituted Iminodiactic Acid Ligands and Uses as Radioisotope Tracers - This disclosure relates to compositions comprising substituted iminodiacetic acid ligands and metal tricarbonyl complexes containing the ligands and derivatives thereof. In certain embodiments, the metal tricarbonyl complexes are used as radioisotope tracers such as renal tracers. In certain embodiments, the metal complexes comprise | 2020-07-23 |
20200231616 | AMINOIODOSILANES AND METHODS OF SYNTHESIZING THESE AMINOIODOSILANES - Methods of synthesizing aminoiodosilanes are disclosed. The reaction to produce the disclosed aminoiodosilanes is represented by the formula: | 2020-07-23 |
20200231617 | METHOD OF COALESCING A SUBSTANCE - Provided is a method of coalescing a substance comprising providing a first mixture comprising a substance, agitating at least a portion of the first mixture under turbulent conditions for a first time period, thereby causing particles comprising and substance to collide and form into larger particles. | 2020-07-23 |
20200231618 | PROCESS FOR EFFICIENT PURIFICATION OF NEUTRAL HUMAN MILK OLIGOSACCHARIDES (HMOs) FROM MICROBIAL FERMENTATION - The present application discloses a simple process for the purification of neutral human milk oligosaccharides (HMOs) produced by microbial fermentation. The process uses a combination of cationic ion exchanger treatment, an anionic ion exchanger treatment, and a nanofiltration and/or electrodialysis step, which allows efficient purification of large quantities of neutral HMOs at high purity. Contrary to the purification currently used in fermentative production of neutral HMOs, the presented process allows the provision of HMOs without the need of a chromatographic separation. The so purified HMOs may be obtained in solid form by spray drying, as crystalline material or as sterile filtered concentrate. The provided HMOs are free of proteins and recombinant material originating from the used recombinant microbial strains and thus very well-suited for use in food, medical food and feed (e.g. pet food) applications. | 2020-07-23 |
20200231619 | MODIFIED NUCLEOTIDES FOR SYNTHESIS OF NUCLEIC ACIDS, A KIT CONTAINING SUCH NUCLEOTIDES AND THEIR USE FOR THE PRODUCTION OF SYNTHETIC NUCLEIC ACID SEQUENCES OR GENES - A modified nucleotide, intended for the synthesis of long chain nucleic acids by enzymatic processes, comprising a “natural” nitrogenous base or a natural nitrogenous base analogue, a ribose or deoxyribose carbohydrate, and at least one phosphate group, characterized in that said nucleotide comprises at least one R group, termed the modifier group, carried by said nitrogenous base or analogue and/or by the oxygen in position 3′ of the ribose or deoxyribose molecule, making it possible to block the polymerization of said nucleotide and/or to allow the interaction of said nucleotide with another molecule, such as a protein, during the nucleic acid synthesis, R comprising at least one functional terminal group. | 2020-07-23 |
20200231620 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION - Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and significantly reduce manufacturing costs. | 2020-07-23 |
20200231621 | CRYSTALLINE OR AMORPHOUS FORM OF STEROID DERIVATIVE FXR AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF - Disclosed are a crystalline or amorphous form of steroid derivative FXR agonist (formula I), and a preparation method therefor, and a crystalline composition and pharmaceutical composition comprising the crystalline or amorphous form, and the use of same in the preparation of a drug for treating or preventing various conditions associated with FXR. | 2020-07-23 |
20200231622 | METHOD FOR PREPARING STEROID DERIVATIVE FXR AGONIST - The present invention falls within the field of pharmaceutical chemistry, and relates to a method for preparing a steroid derivative FXR agonist and relevant intermediates. In particular, the present invention relates to a method for preparing a compound of formula I, comprising reacting a compound of formula 8 with a compound of formula 9 to obtain a compound of formula 10, obtaining a compound of formula 11 from a reaction of the compound of formula 10, and obtaining the compound of formula I from a reaction of the compound of formula 11, as well as the intermediates used, the methods for preparing the intermediates and the use of the intermediates. The reaction conditions of the preparation method are mild, and some of the steps can convert multiple groups simultaneously, thereby effectively shortening the sequence of steps. The preparation method is suitable for industrialized production. | 2020-07-23 |
20200231623 | PENTACYCLIC TRITERPENE COMPOUND AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF - Disclosed are a pentacyclic triterpene compound as shown in general formula (I) and a preparation method therefor. The compound has an effective antagonistic effect on FXR receptors. | 2020-07-23 |
20200231624 | PROTEIN PURIFICATION METHOD - A method is provided for purifying physiologically active proteins, especially antibodies, in order to remove impurities such as DNA contaminants and viruses with minimal loss of physiologically active proteins. The physiologically active protein is introduced into an aqueous solution of low conductivity at a pH of below the isoelectric point of the physiologically active protein to precipitate impurities as particles. The particles are removed, leaving a purified physiologically active protein. | 2020-07-23 |
20200231625 | PEPTIDE WITH ANTIDEPRESSANT ACTIVITY AND THERAPEUTIC EFFECT AGAINST PEPTIDE WITH ANTIDEPRESSANT ACTIVITY AND THERAPEUTIC EFFECT AGAINST ALZHEIMER'S DISEASE - The invention relates to medicine, and more particularly to neurology, and can be used in the treatment of Alzheimer's disease and depression. A peptide is proposed having the general formula acetyl-X-ARG-ARG-amide, where X=-(D-ARG)-ARG-; -(D-LYS)-LYS- or -(D-MET)-MET-. On the basis of the combination of pharmacological properties identified, a preparation could have potential for future clinical use as a nootropic, neuroprotective and antidepressant agent. | 2020-07-23 |
20200231626 | INHIBITION OF GLIADIN PEPTIDES - Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases. | 2020-07-23 |
20200231627 | SYNTHETIC BINDER OF BREAST CANCER STEM CELLS - The present disclosure provides a for peptoid compounds that bind selective to cancer stem cells (CSCs), particularly those associated with breast cancer. Conjugates of the peptoids to detactable labels and therapeutic agent are contemplated as are methods of diagnosing and treating breast cancer. | 2020-07-23 |
20200231628 | NOVEL ANTIMICROBIAL PEPTIDE DERIVED FROM MYXINIDIN PEPTIDE AND USES THEREOF - A novel antimicrobial peptide is derived from myxinidin peptide. The novel antimicrobial peptides (i.e., myxinidin 2 and myxinidin 3) have low cytotoxicity for human cells while exhibiting an excellent antimicrobial activity, and exhibit an anti-inflammatory and a wound healing effect. Thus, they can be advantageously used as an effective ingredient of antibiotics, a cosmetic composition, a food additive, an animal feed additive, biopesticides, and a quasi-drug product or the like. | 2020-07-23 |
20200231629 | BETA-HAIRPIN PEPTIDOMIMETICS - Bet-hairpin peptidomimetics of the general formula (I), cyclo[P | 2020-07-23 |
20200231630 | MOLECULAR GRAFTING OF COMPLEX, BROADLY NEUTRALIZING ANTIBODY EPITOPES - Described herein is a chimeric epitope comprising (a) a conserved donor receptor binding site (RBS) or a neutralizing epitope, or a functional fraction thereof, and (b) an acceptor molecular scaffold or fragment thereof. Another aspect provides a chimeric epitope comprising (a) a conserved donor receptor binding site (RBS) derived from circulating H1 influenza, and (b) an acceptor molecular scaffold derived from non-circulating influenza. Further, compositions and methods for inducing an immune response and vaccination are described herein. | 2020-07-23 |
20200231631 | Hexon protein hypervariable region gene sequence of adenovirus and its application - The invention provides a gene sequence which can encode and express adenovirus hexon protein in vitro, and is represented as SEQ ID NO: 3. Also invented a protein which was translated and expressed by the gene sequence according to the invention, and the invention also relates to the use of the protein as an antigen to immunize rabbits to obtain a polyclonal antibody. The antibody mentioned above can detect adenovirus with high sensitivity and specificity. | 2020-07-23 |
20200231632 | ENGINEERED HEPATITIS B CORE POLYPEPTIDE - Genetically modified HBc polypeptides are provided. | 2020-07-23 |
20200231633 | MGAT1-Deficient Cells for Production of Vaccines and Biopharmaceutical Products - Mannosyl (alpha-1,3)-glycoprotein beta-1,2-N-Acetylglucosaminyltransferase (Mgat1)-deficient cell lines and methods for use of same for producing human immunodeficiency virus (HIV) envelope glycoprotein polypeptides or fragment thereof with terminal mannose-5 glycans are provided. | 2020-07-23 |
20200231634 | TOPICAL COMPOSITIONS AND USES - Provided are chimeric polypeptides that include one or more zinc finger motifs fused to a therapeutic peptide such as botulinum neurotoxins (BoNTs). The zinc finger motif may be located at the C-terminal side of the BoNT and the chimeric polypeptide can optionally include two or more such zinc finger motifs. It said the disclosed chimeric polypeptides can be efficiently delivered to a subject transdermally. | 2020-07-23 |
20200231635 | Systems and methods for the production of diphtheria toxin polypeptides - An expression system and process for the production of Diphtheria toxin polypeptides or mutated forms thereof, such as the toxoid CRM197 polypeptide, in genetically-modified | 2020-07-23 |
20200231636 | CYSTINE KNOT SCAFFOLD PLATFORM - Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided. | 2020-07-23 |
20200231637 | ANTIMICROBIAL ADHESIVE PROTEIN, ANTIMICROBIAL NANOPARTICLE, ANTIMICROBIAL COMPOSITION COMPRISING SAME NANOPARTICLE, AND PREPARATION METHOD FOR SAME COMPOSITION - The present invention relates to an antimicrobial adhesive protein, an antimicrobial nanoparticle, an antimicrobial composition comprising the same nanoparticle, and a preparation method for the same composition and, more particularly, to an antimicrobial adhesive protein in which an antibiotic peptide is linked to a mussel adhesive protein, a mussel adhesive protein derivative in which a tyrosine residue within the antimicrobial adhesive protein is modified with a catechol derivative, an antimicrobial nanoparticle including a metal capable of forming a coordinate bond with a derivative of the mussel adhesive protein and having intrinsic antimicrobial activity, an antimicrobial composition comprising the same nanoparticle, and a preparation method for the same composition. | 2020-07-23 |
20200231638 | STABILIZED ANTI-MICROBIAL PEPTIDES - The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity. | 2020-07-23 |
20200231639 | ACTIVATING MITOTIC CHECKPOINT CONTROL MECHANISMS - Provided herein are compositions and methods for the treatment of cancer by activating the spindle assembly checkpoint (SAC) in cells. In particular, dimerized Mps1 and Spc105/KNL1 constructs are provided as tunable activators of SAC, allowing for control of chromosome segregation accuracy and prevention of aneuploidies that are common in cancer. | 2020-07-23 |
20200231640 | NON-TRANSGENE TRANSFECTION FOR THERAPEUTIC PURPOSES - This disclosure describes compositions and methods involved in tumor suppression and inhibiting infection of cells by pathogens. Generally, the compositions include an mRNA cargo that can provide a therapeutic benefit after being introduced into an epithelial cell. In some cases, the mRNA can encode a polypeptide. In some cases, the polypeptide can suppress epithelial cell proliferation. In other embodiments, the polypeptide can be involved in innate immunity. In various embodiments, the polypeptide can include cathelicin antimicrobial protein (CAMP), calprotectin, S100A8, S100A9, a β-defensin, S100A7, secretory leukocyte inhibitor, lipocalin 2, or lysozyme. In some embodiments, the mRNA can include a stabilizing moiety such as, for example, a 5′ cap or a 3′ extension. | 2020-07-23 |
20200231641 | METHODS AND COMPOSITIONS FOR VISUALIZING SUMO - The present disclosure describes pan-SUMO trapping proteins and fusion proteins comprising the pan-SUMO trapping proteins that are stable and bind SUMO-modified proteins with high avidity. The proteins described herein can be used to detect the localization of SUMO-modified proteins cells. The proteins described herein can be used to identify biomarkers for diseases associated with oxidative stress. They can also be used to diagnose and monitor diseases associated with genotoxic and/or proteotoxic stress conditions. | 2020-07-23 |
20200231642 | PEPTIDE KINASE INHIBITORS AND METHODS OF USE THEREOF - Described herein are isolated regulatory peptides of protein kinase C, chimeric peptides thereof, and their variants. Use of the described peptides, in compositions and methods for treatment of cellular proliferation pathologies is also described. | 2020-07-23 |
20200231643 | CODON OPTIMIZED IL-15 AND IL-15R-ALPHA GENES FOR EXPRESSION IN MAMMALIAN CELLS - The present invention provides for nucleic acids improved for the expression of interleukin-15 (IL-15) in mammalian cells. The invention further provides for methods of expressing IL-15 in mammalian cells by transfecting the cell with a nucleic acid sequence encoding an improved IL-15 sequence. The present invention further provides expression vectors, and IL-15 and IL 15 receptor alpha combinations (nucleic acid and protein) that increase IL-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of IL-15 after DNA, RNA or protein administration in a subject (e.g. a mammal, a human). | 2020-07-23 |
20200231644 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES - Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates). | 2020-07-23 |
20200231645 | Bifunctional compounds - The application discloses compounds useful in treatment of diabetes, weight loss and/or reduction of cardiovascular risks. The compounds are bi-functional and therefore suitable as a simple treatment for patients that may benefit from treatment with both a GLP-1 receptor agonist and a PCSK9 inhibitor. | 2020-07-23 |
20200231646 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE - The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation. | 2020-07-23 |
20200231647 | EXOSOME PRODUCTION METHOD - The method of producing induced lightweight exosomes (iLE) provided by the present invention includes preparing a cell culture containing prescribed cultured cells; supplying at least once an artificially produced synthetic peptide to the cell culture and culturing the cell culture for a prescribed interval; and obtaining exosomes produced by the cultured cells following culturing. Here, the synthetic peptide is provided with: (1) an exosome-inducing peptide sequence and (2) a CPP sequence, and has a total number of amino acid residues of 100 or less. | 2020-07-23 |
20200231648 | Compositions and Methods for Treating Cancer with DuoCARs - Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions. | 2020-07-23 |
20200231649 | TCRS SPECIFIC FOR MINOR HISTOCOMPATIBILITY (H) ANTIGEN HA-1 AND USES THEREOF - The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1 | 2020-07-23 |